Table 2.
Total | Q1 | Q2 | Q3 | Q4 | ||
---|---|---|---|---|---|---|
n = 1160 | n = 290 | n = 290 | n = 290 | n = 290 | P‐value | |
Baseline | ||||||
eGFR | 69.1 ± 14.4 | 68.5 ± 13.5 | 68.4 ± 15.4 | 70.0 ± 13.0 | 69.7 ± 15.6 | 0.41 |
BW | 55.7 ± 9.7 | 64.8 ± 8.4 | 58.1 ± 7.2 | 52.8 ± 6.4 | 47.1 ± 6.7 | <0.01 |
Follow up | ||||||
eGFR | 64.6 ± 14.3 | 64.1 ± 14.5 | 63.7 ± 14.3 | 65.4 ± 13.0 | 65.0 ± 15.1 | 0.41 |
BW | 55.4 ± 10.0 | 63.7 ± 9.2 | 56.9 ± 7.8 | 52.3 ± 7.5 | 47.8 ± 7.4 | <0.01 |
Changes per year | ||||||
eGFR | −1.89 ± 2.98 | −1.78 ± 2.81 | −1.90 ± 2.94 | −1.96 ± 3.11 | −1.93 ± 3.07 | 0.97 |
BW | −0.67 ± 4.93 | −1.06 ± 5.25 | −1.26 ± 4.93 | −0.44 ± 4.71 | 0.16 ± 4.71 | 0.04 |
BW decline 4.5 kg/year | ||||||
21 (100%) | 10 (47.6%) | 9 (42.9%) | 1 (4.8%) | 1 (4.8%) | <0.01 |
BW, bodyweight; eGFR, estimated glomerular filtration rate.